Oui, les patients peuvent éprouver de l'anxiété ou de la dépression en raison de la maladie.
Santé mentaleFibromatoseComplications
#5
Les déformations sont-elles réversibles ?
Les déformations peuvent être partiellement corrigées par la chirurgie, mais pas toujours complètement.
DéformationsChirurgieFibromatose agressive
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque ?
Les antécédents familiaux et les traumatismes locaux sont des facteurs de risque connus.
Facteurs de risqueFibromatoseAntécédents familiaux
#2
Les femmes sont-elles plus à risque ?
Il n'y a pas de preuve claire que le sexe influence le risque de fibromatose agressive.
Facteurs de risqueFibromatoseSexe
#3
Les personnes jeunes sont-elles plus touchées ?
La fibromatose agressive peut survenir à tout âge, mais elle est plus fréquente chez les jeunes adultes.
Fibromatose agressiveÂgeFacteurs de risque
#4
Les antécédents médicaux influencent-ils le risque ?
Oui, des antécédents de tumeurs ou de maladies des tissus mous peuvent augmenter le risque.
Antécédents médicauxFibromatoseFacteurs de risque
#5
Les traitements antérieurs augmentent-ils le risque ?
Certaines interventions chirurgicales peuvent augmenter le risque de développer une fibromatose.
Traitements antérieursFibromatose agressiveFacteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Fibromatose agressive : Questions médicales les plus fréquentes",
"headline": "Fibromatose agressive : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Fibromatose agressive : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-26",
"dateModified": "2026-01-17",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Fibromatose agressive"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Fibrome",
"url": "https://questionsmedicales.fr/mesh/D005350",
"about": {
"@type": "MedicalCondition",
"name": "Fibrome",
"code": {
"@type": "MedicalCode",
"code": "D005350",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.450.565.590.340"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Fibromatose agressive",
"alternateName": "Fibromatosis, Aggressive",
"code": {
"@type": "MedicalCode",
"code": "D018222",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Nicolas Penel",
"url": "https://questionsmedicales.fr/author/Nicolas%20Penel",
"affiliation": {
"@type": "Organization",
"name": "Medical School, Lille University, Lille, France. Electronic address: n-penel@o-lambret.fr."
}
},
{
"@type": "Person",
"name": "Thomas Ryckewaert",
"url": "https://questionsmedicales.fr/author/Thomas%20Ryckewaert",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, Centre Oscar Lambert, Lille, France."
}
},
{
"@type": "Person",
"name": "Ari M Abdullah",
"url": "https://questionsmedicales.fr/author/Ari%20M%20Abdullah",
"affiliation": {
"@type": "Organization",
"name": "Department of Scientific Affairs, Smart Health Tower, Sulaimani, Kurdistan 46001, Iraq."
}
},
{
"@type": "Person",
"name": "Fahmi H Kakamad",
"url": "https://questionsmedicales.fr/author/Fahmi%20H%20Kakamad",
"affiliation": {
"@type": "Organization",
"name": "Department of Scientific Affairs, Smart Health Tower, Sulaimani, Kurdistan 46001, Iraq."
}
},
{
"@type": "Person",
"name": "Sam Sedaghat",
"url": "https://questionsmedicales.fr/author/Sam%20Sedaghat",
"affiliation": {
"@type": "Organization",
"name": "Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Germany; Institute of Diagnostic and Interventional Radiology and Nuclear Medicine, University Hospital Bergmannsheil, Bochum, Germany. Electronic address: Sam.Sedaghat@uksh.de."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "[Aggressive Fibromatosis: Retrospective Analysis of 110 Patients].",
"datePublished": "2023-02-09",
"url": "https://questionsmedicales.fr/article/36758581",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/a-1948-2239"
}
},
{
"@type": "ScholarlyArticle",
"name": "Unusual Presentation of an Uncommon Malignancy: A 74-Year-Old Woman with Aggressive Fibromatosis of the Large Intestine Presenting as a Liver Mass and the Therapeutic Management.",
"datePublished": "2023-10-09",
"url": "https://questionsmedicales.fr/article/37812585",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.12659/AJCR.939862"
}
},
{
"@type": "ScholarlyArticle",
"name": "Desmoid Fibromatosis With TP53 Mutation and Striking Nuclear Pleomorphism.",
"datePublished": "2023-03-13",
"url": "https://questionsmedicales.fr/article/36908221",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/10668969231160255"
}
},
{
"@type": "ScholarlyArticle",
"name": "Oral vinorelbine in young patients with desmoid-type fibromatosis.",
"datePublished": "2023-04-28",
"url": "https://questionsmedicales.fr/article/37114926",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/03008916231169806"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sinonasal Myxoma: A Distinct Entity or a Myxoid Variant of Desmoid Fibromatosis?",
"datePublished": "2023-04-13",
"url": "https://questionsmedicales.fr/article/37059229",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.modpat.2023.100189"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://questionsmedicales.fr/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs du tissu conjonctif et des tissus mous",
"item": "https://questionsmedicales.fr/mesh/D018204"
},
{
"@type": "ListItem",
"position": 5,
"name": "Tumeurs du tissu fibreux",
"item": "https://questionsmedicales.fr/mesh/D018218"
},
{
"@type": "ListItem",
"position": 6,
"name": "Fibrome",
"item": "https://questionsmedicales.fr/mesh/D005350"
},
{
"@type": "ListItem",
"position": 7,
"name": "Fibromatose agressive",
"item": "https://questionsmedicales.fr/mesh/D018222"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Fibromatose agressive - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Fibromatose agressive",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-02-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Fibromatose agressive",
"description": "Comment diagnostiquer la fibromatose agressive ?\nQuels examens d'imagerie sont utilisés ?\nLa biopsie est-elle toujours nécessaire ?\nQuels signes cliniques indiquent une fibromatose agressive ?\nPeut-on confondre cette maladie avec d'autres ?",
"url": "https://questionsmedicales.fr/mesh/D018222#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Fibromatose agressive",
"description": "Quels sont les symptômes courants ?\nLa fibromatose agressive cause-t-elle des douleurs ?\nLes symptômes varient-ils selon l'emplacement ?\nY a-t-il des symptômes systémiques associés ?\nComment évoluent les symptômes dans le temps ?",
"url": "https://questionsmedicales.fr/mesh/D018222#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Fibromatose agressive",
"description": "Peut-on prévenir la fibromatose agressive ?\nY a-t-il des facteurs de risque connus ?\nLes blessures peuvent-elles déclencher la maladie ?\nLe suivi médical aide-t-il à la prévention ?\nLes habitudes de vie influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D018222#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Fibromatose agressive",
"description": "Quels traitements sont disponibles ?\nLa chirurgie est-elle toujours nécessaire ?\nQuels sont les risques de la chirurgie ?\nLa radiothérapie est-elle efficace ?\nY a-t-il des traitements médicamenteux ?",
"url": "https://questionsmedicales.fr/mesh/D018222#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Fibromatose agressive",
"description": "Quelles complications peuvent survenir ?\nLa récidive est-elle fréquente ?\nLes douleurs peuvent-elles devenir chroniques ?\nY a-t-il des risques psychologiques associés ?\nLes déformations sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D018222#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Fibromatose agressive",
"description": "Quels sont les principaux facteurs de risque ?\nLes femmes sont-elles plus à risque ?\nLes personnes jeunes sont-elles plus touchées ?\nLes antécédents médicaux influencent-ils le risque ?\nLes traitements antérieurs augmentent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D018222#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la fibromatose agressive ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique, l'imagerie et la biopsie."
}
},
{
"@type": "Question",
"name": "Quels examens d'imagerie sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM et l'échographie sont couramment utilisés pour évaluer l'étendue de la tumeur."
}
},
{
"@type": "Question",
"name": "La biopsie est-elle toujours nécessaire ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la biopsie est essentielle pour confirmer le diagnostic et exclure d'autres tumeurs."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent une fibromatose agressive ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des masses douloureuses, des déformations et une croissance rapide des tissus peuvent indiquer cette condition."
}
},
{
"@type": "Question",
"name": "Peut-on confondre cette maladie avec d'autres ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec d'autres tumeurs bénignes ou malignes, nécessitant des tests approfondis."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs, des masses palpables et des limitations fonctionnelles."
}
},
{
"@type": "Question",
"name": "La fibromatose agressive cause-t-elle des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la douleur est fréquente et peut être localisée autour de la tumeur."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'emplacement ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon la localisation de la tumeur dans le corps."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes systémiques associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Généralement, il n'y a pas de symptômes systémiques, mais des douleurs locales peuvent être présentes."
}
},
{
"@type": "Question",
"name": "Comment évoluent les symptômes dans le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec le temps si la tumeur n'est pas traitée."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la fibromatose agressive ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthodes de prévention spécifiques, mais un suivi médical régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque connus ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque incluent des antécédents familiaux et des traumatismes locaux."
}
},
{
"@type": "Question",
"name": "Les blessures peuvent-elles déclencher la maladie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traumatismes ou des interventions chirurgicales peuvent être des déclencheurs."
}
},
{
"@type": "Question",
"name": "Le suivi médical aide-t-il à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier peut aider à détecter précocement des signes de récidive."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles le risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de preuves solides que les habitudes de vie influencent le risque de fibromatose."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est chirurgical, mais la radiothérapie peut être envisagée dans certains cas."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est souvent nécessaire pour enlever la tumeur, surtout si elle est invasive."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de la chirurgie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des infections, des saignements et des récidives de la tumeur."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La radiothérapie peut être utilisée pour réduire la taille de la tumeur ou après chirurgie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements médicamenteux ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitements médicamenteux spécifiques pour cette condition."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des récidives, des douleurs chroniques et des déformations."
}
},
{
"@type": "Question",
"name": "La récidive est-elle fréquente ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la récidive est fréquente, surtout si la tumeur n'est pas complètement enlevée."
}
},
{
"@type": "Question",
"name": "Les douleurs peuvent-elles devenir chroniques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs chroniques peuvent se développer si la fibromatose n'est pas traitée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques psychologiques associés ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent éprouver de l'anxiété ou de la dépression en raison de la maladie."
}
},
{
"@type": "Question",
"name": "Les déformations sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les déformations peuvent être partiellement corrigées par la chirurgie, mais pas toujours complètement."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et les traumatismes locaux sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de preuve claire que le sexe influence le risque de fibromatose agressive."
}
},
{
"@type": "Question",
"name": "Les personnes jeunes sont-elles plus touchées ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "La fibromatose agressive peut survenir à tout âge, mais elle est plus fréquente chez les jeunes adultes."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de tumeurs ou de maladies des tissus mous peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les traitements antérieurs augmentent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines interventions chirurgicales peuvent augmenter le risque de développer une fibromatose."
}
}
]
}
]
}
Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Germany; Institute of Diagnostic and Interventional Radiology and Nuclear Medicine, University Hospital Bergmannsheil, Bochum, Germany. Electronic address: Sam.Sedaghat@uksh.de.
Department for Radiology and Neuroradiology, University Hospital Schleswig-Holstein, Campus Kiel, Germany; Institute of Diagnostic and Interventional Radiology and Nuclear Medicine, University Hospital Bergmannsheil, Bochum, Germany.
Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany; Department for Interventional Radiology and Neuroradiology, Klinikum Hochsauerland, Arnsberg, Germany.
Aggressive fibromatosis, histologically classified as benign due to the absence of metastasis, is characterised by locally invasive and destructive growth with high recurrence rates after resection. F...
BACKGROUND Desmoid tumors are a fibroblastic proliferation of soft tissues, with an extreme inclination for local dissemination and recurrence. Surgical excision is the usual treatment choice, with da...
Desmoid fibromatosis is a myofibroblastic neoplasm of intermediate biologic potential, which has a strong predilection for local recurrence but does not metastasize. Arranged in long, sweeping fascicl...
Desmoid-type fibromatosis are rare intermediate tumors in children and adolescents. Owing to local aggressiveness and relapse, systemic treatment for symptomatic advanced or progressive forms is recom...
A retrospective review of young patients (<25 years old) with advanced or progressive desmoid type fibromatosis treated with oral vinorelbine in eight large centers of the Société Française des Cancer...
From 2005 to 2020, 24 patients (median age 13.9 years [range, 1.0-23.0]) received oral vinorelbine. Median number of prior systemic lines of treatment was 1 (range, 0-2), mainly based on intravenous l...
Oral vinorelbine seems to be effective to control advanced or progressive desmoid type fibromatosis in young patients, with a well-tolerated profile. These results support testing this drug as first-l...
Sinonasal myxoma (SNM) is a rare benign mesenchymal tumor that arises in the sinonasal cavity or maxilla and almost exclusively affects young children. Currently, it is considered a specific entity, b...
Desmoid-type fibromatosis (DF) is a rare monoclonal, fibroblastic proliferation characterized by an unpredictable and variable clinical course. We present the case of a 56-year-old woman who underwent...
Neuromuscular choristoma (NMC) is a rare peripheral nerve lesion characterized by abnormal presence of muscle within nerve. Associated desmoid-type fibromatosis (NMC-DTF) often develops. We report...
Our institutional database was searched for all NMC cases. Inclusion criteria were 1) confirmed diagnosis of NMC with or without biopsy, and 2) available PET and MRI studies. PET data included SUVmax ...
Our cohort consisted of 9 patients with NMC, 8 cases involving sciatic nerve and 1 of brachial plexus. On PET imaging, all NMC-affected nerve segments showed significantly higher FDG uptake (SUVmax/me...
All NMCs were more FDG avid compared to both normal skeletal muscle and contralateral unaffected nerve, arguing against the presence of heterotopic muscle in NMC as the source of FDG avidity. FDG avid...
The aim of this study is to evaluate the prevalence, determinants and prognostic value of pain at diagnosis in patients with desmoid-type fibromatosis (DF). We selected patients from the ALTITUDES coh...
In recent years, there has been a change in the therapeutic landscape of desmoid-type fibromatosis (DF). Watchful waiting is now preferred over initial local treatments such as surgery and radiotherap...
We established a retrospective dataset of patients treated with sorafenib in our centre, Ghent University Hospital, for progressive DF. Patient demographics, disease characteristics, response to thera...
Eleven patients with DF were treated with sorafenib between 2020 and 2024. Median treatment duration was 20.4 months (95% confidence interval [CI], 10.0-NR). 36.4% achieved partial response, 54.5% sta...
Real-life data on the use of sorafenib in the treatment of DF is consistent with published data in clinical trial setting. Sorafenib is an effective treatment option for progressive DF although associ...
Sorafenib is currently one of the recommended treatments for symptomatic patients with desmoid-type fibromatosis (DTF). In this study, we aim to assess the clinical efficacy and tolerability of sorafe...
Patients aged>18 years with a histological diagnosis of DTF and who have received sorafenib were enroled in this prospective observational study. Demographic data, clinical profile, the initial dose o...
A total of 104 patients were enroled in the study. The median age of the study population was 32 (range, 18-81) years, and 66.35% of patients were females. On response assessment, ORR was 46.1% and st...
Sorafenib has good activity in DTF, but it is associated with significant toxicity. The adverse effect profile is distinct in Indian patients with higher HFSR and alopecia. Due to the high rate of dos...